ENHERTU Followed by THP Approved in China for the Neoadjuvant Treatment of HER2+ve Breast Cancer
“As the first approval of ENHERTU globally for the neoadjuvant treatment of HER2 positive early-stage breast cancer and the first HER2 directed antibody drug conjugate approved in China in this setting, ENHERTU followed by THP offers patients in China a new treatment option with the opportunity to reach a pathologic complete response and the potential for improved long-term outcomes,” said Michio Hayashi, China President, Daiichi Sankyo. “This third approval of ENHERTU in the last three months and seventh approval in three years reinforces the rapid progress we are making in bringing ENHERTU to more patients in China, where there is a high incidence of breast cancer and a continued need for new treatment approaches.
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.